• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Neogen Corporation

    11/14/24 4:28:12 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NEOG alert in real time by email
    SC 13G 1 s013024a.htm SCHEDULE 13G



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549




    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. )*





    Neogen Corporation

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    640491106

    (CUSIP Number)



    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)





    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒
    Rule 13d-1(b)
    ☐
    Rule 13d-1(c)
    ☐
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    CUSIP No. 640491106
    SCHEDULE 13G
    Page 2 of 6 Pages

    1
    NAMES OF REPORTING PERSONS
     
    Select Equity Group, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
    (b) ☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    13,241,197
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    13,241,197
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
     
    13,241,197
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    6.1%*
    12
    TYPE OF REPORTING PERSON
     
    IA
    * Beneficial ownership based on 216,698,138 shares of common stock outstanding as of August 31, 2024, as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on October 10, 2024.



    CUSIP No. 640491106
    SCHEDULE 13G
    Page 3 of 6 Pages

    1
    NAMES OF REPORTING PERSONS
     
    George S. Loening
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
    (b) ☐
    3
    SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    13,241,197
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    13,241,197
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
     
    13,241,197
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    6.1%*
    12
    TYPE OF REPORTING PERSON
     
    IN/HC
    * Beneficial ownership based on 216,698,138 shares of common stock outstanding as of August 31, 2024, as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on October 10, 2024.



    Item 1(a)
    Name of Issuer:
       

    Neogen Corporation
       
    Item 1(b)
    Address of Issuer’s Principal Executive Offices:
       
     
    620 Lesher Place
     
    Lansing, Michigan 48912
       
       
    Items 2(a)
    Name of Person Filing:
       
     
    This Schedule 13G is being filed jointly by Select Equity Group, L.P., a Delaware limited partnership (“Select LP”) and George S. Loening (“Loening”), who is the majority owner of Select LP and managing member of its general partner. Select LP and Loening are sometimes jointly referred to herein as the “Select Reporting Persons.”
       
    Item 2(b)
    Address of Principal Business Office:
     
    The business address of each of the Select Reporting Persons is:
     
    380 Lafayette Street, 6th Floor
     
    New York, New York 10003
       
    Item 2(c)
    Citizenship:
       
     
    George S. Loening is a United States citizen.
       
    Item 2(d)
    Title of Class of Securities:
       
     
    Common Stock
       
    Item 2(e)
    CUSIP Number:
       
     
    640491106
       
       
    Item 3
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is:


    (a)
    ☐ Broker or dealer registered under Section 15 of the Act;
    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Act;
    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Act;
    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)
    ☒ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)
    ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)
    ☒ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)
    ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)
    ☐ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)
    ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).


    4



    Item 4
    Ownership:
       
     
    The information required by Items 4(a)-(c), as of the date hereof, is set forth in Rows 5-11 of the cover page hereto for each Select Reporting Person and is incorporated herein by reference for each such Select Reporting Person.
       
       
    Item 5
    Ownership of Five Percent or Less of a Class:
       
     
    If this statement is being filed to report the fact that as of the date hereof a reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐ .
       
       
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person:
       
     
    N/A
       
       
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
     
    See Exhibit 99.1
       
       
    Item 8
    Identification and Classification of Members of the Group:
       
     
    N/A
       
       
    Item 9
    Notice of Dissolution of Group:
       
     
    N/A
       
       
    Item 10
    Certification:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    5



    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.


     
    SELECT EQUITY GROUP, L.P.
       
     
    By: Select Equity GP, LLC, its General Partner
       
     
    By: /s/ George S. Loening
     
    Name: George S. Loening
     
    Title: Managing Member
       
       
       
     
    /s/ George S. Loening
     
    George S. Loening, an individual
       
       
    Dated: Novermber 14, 2024
     


    6

    Get the next $NEOG alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NEOG

    DatePrice TargetRatingAnalyst
    7/29/2025Outperform → Mkt Perform
    William Blair
    12/19/2024$15.00Buy
    Guggenheim
    6/16/2023$22.00Overweight
    Wells Fargo
    11/22/2022Mkt Perform → Outperform
    William Blair
    7/12/2022$25.00Neutral
    Piper Sandler
    More analyst ratings

    $NEOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gupta Aashima bought $99,987 worth of shares (16,000 units at $6.25), increasing direct ownership by 270% to 21,917 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    5/12/25 2:30:47 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Woteki Catherine E bought $29,831 worth of shares (5,770 units at $5.17), increasing direct ownership by 77% to 13,244 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/25/25 4:32:35 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Borel James C bought $149,700 worth of shares (30,000 units at $4.99), increasing direct ownership by 50% to 90,474 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    4/25/25 2:45:19 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that William Boehm has chosen to retire from the Company's Board of Directors, effective October 23, 2025. Mr. Boehm has served on Neogen's Board since 2011 and currently serves on the Compensation & Talent Management Committee and chairs the Audit Committee. "On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors. "Bill's insight, guidance, and commitment to our mission have been invaluable in shaping Neogen's path forward. His contributions

    8/14/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Establishes Relationship with Biomatter

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has entered into an arrangement with Biomatter, a leading enzyme design company, to leverage Biomatter's proprietary Intelligent Architecture™ platform and Neogen's expertise in the field of analytical development and technology to create new enzyme-based products. Biomatter's Intelligent Architecture™ platform, based on AI and Physical modelling, enables the design of enzymes with unique capabilities, dramatically expanding how they can be used in food safety related applications. "This relationship marks a significant step forward in advancing food security," said Dr. Jason Lilly,

    8/11/25 8:45:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Fourth-Quarter 2025 Results

    Revenue of $225.5 million. Net loss of $612.2 million due to non-cash goodwill impairment; $(2.82) per diluted share. Adjusted Net Income1 of $11.3 million; $0.05 per diluted share. Adjusted EBITDA1 of $40.6 million. 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the fourth quarter ended May 31, 2025. "The softer end-market conditions continued in the fourth quarter, with elevated trade uncertainty and the cumulative effect of the last four years of inflation on food production," said John Adent, Neogen's President and Chief Executive Officer. "We believe the Food Safety end mar

    7/29/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO Naemura David H. was granted 230,203 shares, increasing direct ownership by 375% to 291,637 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    8/19/25 6:49:44 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Legal Officer Rocklin Amy M was granted 119,705 shares, increasing direct ownership by 325% to 156,556 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    8/19/25 6:45:13 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Accounting Officer Moylan John Patrick was granted 18,416 shares, increasing direct ownership by 142% to 31,371 units (SEC Form 4)

    4 - NEOGEN CORP (0000711377) (Issuer)

    8/19/25 6:36:37 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Neogen downgraded by William Blair

    William Blair downgraded Neogen from Outperform to Mkt Perform

    7/29/25 3:32:27 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Guggenheim initiated coverage on Neogen with a new price target

    Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00

    12/19/24 8:18:19 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Wells Fargo initiated coverage on Neogen with a new price target

    Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00

    6/16/23 7:34:39 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Financials

    Live finance-specific insights

    View All

    Neogen Announces Fourth-Quarter 2025 Results

    Revenue of $225.5 million. Net loss of $612.2 million due to non-cash goodwill impairment; $(2.82) per diluted share. Adjusted Net Income1 of $11.3 million; $0.05 per diluted share. Adjusted EBITDA1 of $40.6 million. 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the fourth quarter ended May 31, 2025. "The softer end-market conditions continued in the fourth quarter, with elevated trade uncertainty and the cumulative effect of the last four years of inflation on food production," said John Adent, Neogen's President and Chief Executive Officer. "We believe the Food Safety end mar

    7/29/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Fourth-Quarter Earnings Release Date

    Neogen® Corporation (NASDAQ:NEOG) will issue its fourth-quarter earnings release before the opening of the market on Tuesday, July 29, 2025. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing: Toll-Free - North America: 1-800-549-8228 International: (+1) 646-564-2877 Conference ID: 65461 The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "Events & Presentations" subheading. A replay of the conference call and webcast will be available shortly following the conclusio

    7/8/25 4:05:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Announces Third-Quarter 2025 Results

    Revenue of $221.0 million. Net loss of $11.0 million; $(0.05) per diluted share. Adjusted Net Income1 of $20.9 million; $0.10 per diluted share. Adjusted EBITDA1 of $48.5 million. Updating full-year guidance. 1 Non-GAAP financial measures; see explanations and reconciliations that follow. Neogen Corporation (NASDAQ:NEOG) announced today the results of the third quarter ended February 28, 2025. "During the third quarter, we continued to make good progress on the integration and saw a solid underlying performance in our Food Safety segment," said John Adent, Neogen's President and Chief Executive Officer. "The quarter was impacted by lower sample collection revenue, but we made s

    4/9/25 7:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Leadership Updates

    Live Leadership Updates

    View All

    Neogen Announces Board Transition with Appointment of Avi Pelossof and the Retirement of William Boehm

    Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that William Boehm has chosen to retire from the Company's Board of Directors, effective October 23, 2025. Mr. Boehm has served on Neogen's Board since 2011 and currently serves on the Compensation & Talent Management Committee and chairs the Audit Committee. "On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors. "Bill's insight, guidance, and commitment to our mission have been invaluable in shaping Neogen's path forward. His contributions

    8/14/25 4:15:00 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Corporation Announces Appointment of Mike Nassif as CEO and President

    Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Mike Nassif as its new Chief Executive Officer and President, effective August 11, 2025. He also will join Neogen's Board of Directors at that time. Mr. Nassif succeeds John Adent who will, as previously announced, step down after an eight-year career at the company. Mr. Nassif brings a wealth of experience and a proven track record of success in the healthcare and diagnostics industry. Mr. Nassif joins Neogen from Siemens Healthineers, where he was Global President of the Point-of-Care Diagnostics business and instrumental in driving significant growth. "I am very exci

    7/24/25 9:00:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen® Announces CEO Transition

    Board has Formed Search Committee and Engaged Leading Executive Search Firm Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced that John Adent, the Company's CEO and President, will be stepping down after an eight-year career at the Company. Mr. Adent will continue to serve in his existing roles until his successor has been appointed. Neogen's Board of Directors has formed a special committee, comprising Board Chair Jim Borel, Thierry Bernard and Jeff Capello, to direct the search for the Company's next CEO and has engaged a leading global executive search firm. The special committee will also support Mr. Adent and the leadership team as they

    4/9/25 7:01:00 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 4:28:12 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Neogen Corporation

    SC 13G - NEOGEN CORP (0000711377) (Subject)

    11/14/24 11:16:20 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G/A filed by Neogen Corporation (Amendment)

    SC 13G/A - NEOGEN CORP (0000711377) (Subject)

    2/13/24 5:09:41 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NEOG
    SEC Filings

    View All

    Neogen Corporation filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    8/14/25 4:18:12 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-K filed by Neogen Corporation

    10-K - NEOGEN CORP (0000711377) (Filer)

    7/30/25 1:33:06 PM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Neogen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEOGEN CORP (0000711377) (Filer)

    7/29/25 7:01:34 AM ET
    $NEOG
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care